Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGFR BP102 in BLIS Subtype of Triple-negative Breast Cancer
NCT05806060Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Apr 2023; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05806060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806060.